Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma : laboratory evidence and clinical implications
© 2022 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd..
Venous thrombosis is a frequent complication in cancer and is associated with high morbidity and mortality. Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related death worldwide, and it is associated with preexisting cirrhosis in 90% of cases. Patients with cirrhosis acquire complex alterations in their haemostatic system that may predispose them to bleed or thrombotic complications. There is growing evidence that HCC may tilt the haemostatic equilibrium in cirrhosis towards hypercoagulability, thus increasing the risk of venous thrombosis. Previously described mechanisms of HCC-driven thrombophilia include thrombocytosis and increased platelet activation/function, increased fibrinogen concentration/polymerization, enhanced thrombin generation, hypofibrinolysis, and release of tissue factor-expressing microvesicles. Nevertheless, there are currently no specific guidelines on risk stratification and management of thromboprophylaxis in patients with cirrhosis and HCC. Our review endeavours to summarize the latest findings on epidemiology, risk factors and pathogenesis of non-malignant venous thrombosis in patients with cirrhosis and HCC, and provide evidence in support of tailored management of thrombotic risk in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Liver international : official journal of the International Association for the Study of the Liver - 42(2022), 6 vom: 20. Juni, Seite 1229-1240 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zanetto, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 10.06.2022 Date Revised 22.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/liv.15183 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336617933 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336617933 | ||
| 003 | DE-627 | ||
| 005 | 20231225232543.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/liv.15183 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336617933 | ||
| 035 | |a (NLM)35129286 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zanetto, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma |b laboratory evidence and clinical implications |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2022 | ||
| 500 | |a Date Revised 22.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd. | ||
| 520 | |a Venous thrombosis is a frequent complication in cancer and is associated with high morbidity and mortality. Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related death worldwide, and it is associated with preexisting cirrhosis in 90% of cases. Patients with cirrhosis acquire complex alterations in their haemostatic system that may predispose them to bleed or thrombotic complications. There is growing evidence that HCC may tilt the haemostatic equilibrium in cirrhosis towards hypercoagulability, thus increasing the risk of venous thrombosis. Previously described mechanisms of HCC-driven thrombophilia include thrombocytosis and increased platelet activation/function, increased fibrinogen concentration/polymerization, enhanced thrombin generation, hypofibrinolysis, and release of tissue factor-expressing microvesicles. Nevertheless, there are currently no specific guidelines on risk stratification and management of thromboprophylaxis in patients with cirrhosis and HCC. Our review endeavours to summarize the latest findings on epidemiology, risk factors and pathogenesis of non-malignant venous thrombosis in patients with cirrhosis and HCC, and provide evidence in support of tailored management of thrombotic risk in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a HCC | |
| 650 | 4 | |a PVT | |
| 650 | 4 | |a cirrhosis | |
| 650 | 4 | |a coagulation | |
| 650 | 4 | |a fibrinolysis | |
| 650 | 4 | |a platelets | |
| 650 | 4 | |a thrombosis | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Hemostatics |2 NLM | |
| 700 | 1 | |a Campello, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Pelizzaro, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Farinati, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Burra, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Simioni, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Senzolo, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver international : official journal of the International Association for the Study of the Liver |d 2003 |g 42(2022), 6 vom: 20. Juni, Seite 1229-1240 |w (DE-627)NLM124147356 |x 1478-3231 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:6 |g day:20 |g month:06 |g pages:1229-1240 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/liv.15183 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 6 |b 20 |c 06 |h 1229-1240 | ||